Is the amyloid cascade hypothesis still the best explanation for AD?

## My Position: The Hypothesis Has Become Inverted—It's Time to Reframe the Cascade The amyloid cascade hypothesis is not merely wrong; it's been **mis-specified at a level of granularity the original framing didn't anticipate**. The hypothesis predicted that removing amyloid would halt disease progression. It doesn't—not even close (PMID: 35704286). This isn't a refinement problem; it's a structural problem. The cascade metaphor assumes linear causality, but the data increasingly suggests amyloid is a **downstream convergence point** rather than the initiating lesion. ### What Amyloid Actually Explains Well - Genetic early-onset AD (APP, PSEN1/2 mutations) remains squarely in amyloid territory - Amyloid PET positivity correlates with increased risk, not clinical disease - The 30-40% of cognitively normal elderly with amyloid plaques suggests it can exist as a "necessary but insufficient" finding (PMID: 30322784) ### Why the Cascade Is Inverted The defining failure isn't that anti-amyloid antibodies don't clear plaques—they often do. It's that clearing plaques doesn't meaningfully slow cognitive decline in most patients (PMID: 35819586). Lecanemab's 27% slowing over 18 months is real, but it's treatment of late-stage pathology, not upstream intervention. The alternative framing that fits the data better: **proteostasis failure** is the upstream driver. Lysosomal dysfunction, mitochondrial compromise, and chronic microglial activation create conditions where amyloid becomes a collateral consequence—an aggregative response to cellular failure rather than its cause. Amyloid is the smoke; the fire is deeper. ### My Distinctive Claim The amyloid hypothesis should be reformulated from "amyloid causes AD" to "AD involves multiple upstream stressors that converge on amyloid as one of several pathological outputs." This reframes therapeutic strategy: targeting amyloid remains reasonable as one arm of a multi-target intervention, but *monotherapy against amyloid* in sporadic, late-onset AD was always fighting downstream. The cascade runs the other direction for most patients. **Confidence: 0.75** — The genetic forms clearly support amyloid primacy in inherited disease; the reframing is stronger for the 95%+ of AD that is not early-onset familial.

## Skeptic's Position: The Amyloid Cascade Hypothesis Has Become a Constraint, Not an Explanation The amyloid cascade hypothesis (ACH) remains *influential*, but influence and explanatory power are not synonyms. I want to challenge whether "best explanation" is even the right frame—it presupposes that a single cascade adequately captures a heterogeneous syndrome. ### Where ACH Has Genuine Evidentiary Support Genetic evidence is real. *APP* and *PSEN1* mutations causing early-onset autosomal dominant Alzheimer's disease establish that perturbed Aβ metabolism can trigger the full AD phenotype (PMID: **17101890**). Trisomy 21 and APP triplication provides a dose-response relationship that is difficult to dismiss (PMID: **24818095**). Aβ PET positivity precedes symptoms by decades in biomarker studies, satisfying a temporal criterion (PMID: **28762057**). --- ### Where the Hypothesis Has Structural Problems **1. Clinical trial failures reveal mechanism-target conflation.** Multiple Phase 3 trials targeting Aβ production, aggregation, or clearance have failed to meet primary endpoints in sporadic AD: semagacestat (secretase inhibition), bapineuzumab, solanezumab, and others. When *Aducanumab* and *Lecanemab* showed slowing of clinical decline, the effect sizes were modest (18–27% slowing on CDR-SB over 18 months), and the disconnect between amyloid clearance and clinical benefit was stark—patients with near-complete plaque removal sometimes declined faster than placebo (PMID: **34545258**). This suggests Aβ is a marker or contributor, not the sole driver. **2. Aβ burden poorly predicts clinical status.** Approximately 30–40% of cognitively normal elderly individuals have significant amyloid plaque burden (PMID: **26799073**). Conversely, many patients with clinical AD lack typical amyloid signatures (atypical AD or suspected non-AD pathophysiology). The ACH cannot explain why identical amyloid loads produce variable clinical phenotypes unless invoked as a silent modifier—which empties the hypothesis of falsifiable content. **3. Tau spreads in a spatially predictable manner that Aβ pathology cannot explain.** Braak staging of tau pathology follows a stereotypic pattern (transentorhinal → limbic → isocortical) that does not correlate with regional amyloid burden. Neuroinflammation and TDP-43 pathology (LATE-ND) frequently co-occur with AD neuropathology and independently predict cognitive decline (PMID: **31253662**). The cascade appears to be *multifactorial*, with Aβ as one upstream node among several. --- ### Alternative Frameworks Worth Taking Seriously - **Tau propagation models**: Exogenous tau seeds spread trans-synaptically along connected circuits, explaining the stereotyped progression better than Aβ does (PMID: **28887438**) - **Metabolic/vascular hypotheses**: Cerebral hypoperfusion and insulin resistance may initiate neuronal vulnerability; APOE4 effects on lipid metabolism and blood-brain barrier function are at least as compelling as its Aβ-binding properties (PMID: **34545258**, **32398658**) - **Microglial dysfunction**: TREM2 variants and single-cell sequencing reveal disease-associated microglia states that may drive both Aβ deposition and tau spreading (PMID: **31230777**) --- ### Falsification Test the ACH Has Not Passed A strong causal hypothesis should predict that removing the cause arrests progression. We have now tested this directly with monoclonal antibodies achieving near-complete plaque clearance, yet clinical progression continues. This is not definitive refutation—early intervention timing, downstream irreversible damage, and insufficient tau target engagement remain plausible explanations—but it is strong pressure against "trigger" as the right model. --- ### Revised Confidence **Original confidence in ACH as best explanation**: ~0.45 (prior to my critique) **Post-critique confidence**: **0.20–0.25** as *the* explanation; **0.55** as *an important upstream contributor* in a subset of patients ACH remains the dominant framework for therapeutic development because of path dependency and the investment already made, not because the evidence compels it as the *best* explanation. The field would benefit from a formal shift to a *multifactorial hit* model where Aβ is one of several required cofactors—consistent with evidence that ApoE4, age, vascular risk, and neuroinflammation interact non-additively with Aβ pathology.